{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:01:06Z","timestamp":1788966066366,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jjcc.2018.10.003","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T21:17:25Z","timestamp":1541798245000},"page":"102-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Update of acute and long-term tolvaptan therapy"],"prefix":"10.1016","volume":"73","author":[{"given":"Teruhiko","family":"Imamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2018.10.003_bib0005","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/clpt.2013.147","article-title":"Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients","volume":"94","author":"Kinugawa","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1536\/ihj.54.377","article-title":"Tolvaptan can improve clinical course in responders","volume":"54","author":"Imamura","year":"2013","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1536\/ihj.14-332","article-title":"Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study)","volume":"56","author":"Kinugawa","year":"2015","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0020","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1253\/circj.CJ-13-0187","article-title":"Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry)","volume":"77","author":"Sato","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0025","unstructured":"Guidelines for Diagnosis and Treatment of Acute and Chronic Heart Failure. 2018. http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2017_tsutsui_h.pdf."},{"key":"10.1016\/j.jjcc.2018.10.003_bib0030","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.jacc.2017.04.042","article-title":"Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure","volume":"69","author":"Matsue","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0035","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/hc1102.105264","article-title":"BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis","volume":"103","author":"Francis","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0045","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0050","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jjcc.2018.10.003_bib0055","doi-asserted-by":"crossref","DOI":"10.1536\/ihj.18-119","article-title":"Effects of tolvaptan on volume overload in patients with heart failure meta-analysis of randomized controlled trials","volume":"59","author":"Kinugawa","year":"2018","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0060","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1007\/s00380-015-0780-z","article-title":"Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure","volume":"31","author":"Matsukawa","year":"2016","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0065","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00380-017-1067-3","article-title":"The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients","volume":"33","author":"Kiuchi","year":"2018","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0070","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0075","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jacc.2016.12.035","article-title":"Short-term effects of tolvaptan in patients with acute heart failure and volume overload","volume":"69","author":"Konstam","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0080","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1253\/circj.CJ-17-0311","article-title":"Tolvaptan, is it a trump to worsening renal function?","volume":"81","author":"Momomura","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0085","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00380-016-0872-4","article-title":"Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction","volume":"32","author":"Hanatani","year":"2017","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/hrt.57.1.17","article-title":"Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics","volume":"57","author":"Bayliss","year":"1987","journal-title":"Br Heart J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ehf2.12088","article-title":"Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure","volume":"3","author":"Jujo","year":"2016","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0100","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1536\/ihj.16-249","article-title":"Who needs longer tolvaptan treatment?","volume":"58","author":"Kinugawa","year":"2017","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00380-017-1048-6","article-title":"Favorable effects of early tolvaptan administration in very elderly patients after repeat hospitalizations for acute decompensated heart failure","volume":"33","author":"Kinoshita","year":"2018","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0115","first-page":"206","article-title":"Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure","volume":"18","author":"Niikura","year":"2017","journal-title":"Anatol J Cardiol"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0120","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1253\/circj.CJ-17-0986","article-title":"Novel risk score efficiently prevents tolvaptan-induced hypernatremic events in patients with heart failure","volume":"82","author":"Kinugawa","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0125","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1253\/circj.CJ-12-0971","article-title":"Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients \u2013 association between non-responders and chronic kidney disease","volume":"77","author":"Imamura","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0130","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1253\/circj.CJ-12-1328","article-title":"Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients","volume":"77","author":"Imamura","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0135","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1253\/circj.CJ-14-0244","article-title":"Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure","volume":"78","author":"Imamura","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0140","first-page":"17","article-title":"Urine aquaporin-2: a promising marker of response to the arginine vasopressin type-2 antagonist, tolvaptan in patients with congestive heart failure","author":"Imamura","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0145","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1536\/ihj.16-007","article-title":"Tolvaptan reduces long-term total medical expenses and length of stay in aquaporin-defined responders","volume":"57","author":"Imamura","year":"2016","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0150","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1536\/ihj.13-326","article-title":"Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure: design and rationale of the AQUA-TLV study","volume":"55","author":"Imamura","year":"2014","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0155","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1536\/ihj.15-298","article-title":"Mid-term administration of tolvaptan improves renal function accompanied by dose-reduction in furosemide in aquaporin-defined responders","volume":"56","author":"Imamura","year":"2015","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1536\/ihj.16-625","article-title":"Impact of continuous administration of tolvaptan on preventing medium-term worsening renal function and long-term adverse events in heart failure patients with chronic kidney disease","volume":"59","author":"Nakano","year":"2018","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0165","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1536\/ihj.17-099","article-title":"Tolvaptan improves prognosis in responders with acute decompensated heart failure by reducing the dose of loop diuretics","volume":"59","author":"Nakamura","year":"2018","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0170","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1253\/circj.CJ-17-0554","article-title":"Safety and efficacy of long-term use of tolvaptan in patients with heart failure and chronic kidney disease","volume":"81","author":"Uemura","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0175","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","article-title":"Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction","volume":"49","author":"Udelson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0180","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1536\/ihj.16-227","article-title":"Prognostic impacts of hyponatremia, renal dysfunction, and high-dose diuretics during a 10-year study period in 4,087 Japanese heart failure patients","volume":"57","author":"Imamura","year":"2016","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0185","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1536\/ihj.15-297","article-title":"Tolvaptan prolongs blockage of the vasopressin type II receptor over 24hours in responders with stage D heart failure","volume":"57","author":"Imamura","year":"2016","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0195","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0200","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"issue":"Suppl. 1","key":"10.1016\/j.jjcc.2018.10.003_bib0205","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s10557-011-6303-y","article-title":"Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"25","author":"Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.jjcc.2018.10.003_bib0210","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study)","volume":"25","author":"Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0215","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2011.08.005","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction","volume":"17","author":"Udelson","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0220","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jjcc.2015.09.020","article-title":"Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure","volume":"67","author":"Kimura","year":"2016","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0225","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","article-title":"Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction","volume":"22","author":"Matsue","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0230","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijcard.2016.06.156","article-title":"Effects of short-term administration of tolvaptan after open heart surgery","volume":"220","author":"Matsuyama","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0235","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1253\/circj.CJ-16-1122","article-title":"Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction- prospective randomized controlled study","volume":"81","author":"Tamaki","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2018.10.003_bib0240","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","article-title":"Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment \u2013 results from the K-STAR Study","volume":"82","author":"Inomata","year":"2017","journal-title":"Circ J"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508718302880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508718302880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:00:24Z","timestamp":1760274024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508718302880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0914508718302880"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2018.10.003","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update of acute and long-term tolvaptan therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2018.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}